Publication Name	World Journal of Diabetes
Manuscript ID	76220
Country	India

Received	2022-03-07 18:15
Peer-Review Started	2022-03-07 18:16
To Make the First Decision
Return for Revision	2022-04-17 20:51
Revised	2022-04-19 16:38
Second Decision	2022-05-18 03:06
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-05-23 00:14
Articles in Press	2022-05-23 00:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-05-31 07:43
Publish the Manuscript Online	2022-06-08 02:31

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Letter to the Editor
Article Title	Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
Manuscript Source	Unsolicited Manuscript
All Author List	Awadhesh Kumar Singh and Ritu Singh
ORCID	Author(s) ORCID Number Awadhesh Kumar Singh http://orcid.org/0000-0002-8374-4536 Ritu Singh http://orcid.org/0000-0003-1779-0638
Funding Agency and Grant Number
Corresponding Author	Awadhesh Kumar Singh, MBBS, MD, Consultant Physician-Scientist, Intermediate Editor, Senior Postdoctoral Fellow, Senior Researcher, Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, 133A, Lenin Sarani, Kolkata 700013, West Bengal, India. draksingh_2001@yahoo.com
Key Words	DPP-4 inhibitors; SGLT-2 inhibitors; GLP-1 receptor agonists; Cardiovascular outcomes; Renal outcomes
Core Tip	Despite the newer anti-diabetic agents such as SGLT-2 inhibitors (SGLT-2Is) and GLP-1 receptor agonists have taken the center stage in the management of type 2 diabetes mellitus due to additional cardiac and renal benefits, the role of DPP-4 inhibitors (DPP-4Is) cannot be undermined. HbA1c lowering potential of DPP-4Is are nearly similar to SGLT-2Is and surprisingly larger in a background of modest baseline HbA1c compared with SGLT-2Is. Moreover, the HbA1c lowering abilities of SGLT-2Is are compromised with declining renal function while DPP-4Is reduce HbA1c favorably in people with chronic kidney disease regardless of impaired kidney functions.
Publish Date	2022-06-08 02:31
Citation	Singh AK, Singh R. Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors. World J Diabetes 2022; 13(6): 466-470
URL	https://www.wjgnet.com/1948-9358/full/v13/i6/466.htm
DOI	https://dx.doi.org/10.4239/wjd.v13.i6.466

Full Article (PDF)	WJD-13-466.pdf
Full Article (Word)	WJD-13-466.docx
Manuscript File	76220_Auto_Edited-LS.docx
Answering Reviewers	76220-Answering reviewers.pdf
Audio Core Tip	76220-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	76220-Conflict-of-interest statement.pdf
Copyright License Agreement	76220-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	76220-Language certificate.pdf
Peer-review Report	76220-Peer-review(s).pdf
Scientific Misconduct Check	76220-Bing-Chang KL-2.png
Scientific Editor Work List	76220-Scientific editor work list.pdf
CrossCheck Report	76220-CrossCheck report.pdf